Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Theravance Biopharma

27/02/2023 22:03

* Theravance Biopharma Inc  TBPH.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 17 cents per share.
    * Revenue fell 2% to $14.65 million from a year ago;
analysts
expected $15.73 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 15 cents​.
    * The mean earnings estimate of analysts had fallen by
about 95.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Theravance Biopharma Inc shares had fallen by 12.0% this
quarter.
    * The company reported a quarterly loss of $10.36 million.
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $12.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
27 at 10:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.17          -0.15          Beat
 Sep. 30 2022      -0.18          -0.21          Missed
 Jun. 30 2022      0.11           -0.09          Missed
 Mar. 31 2022      -0.11          -0.22          Missed